Method of treating viral infections
A virus infection, ribavirin technology, applied in antiviral agents, pharmaceutical formulations, medical preparations containing active ingredients, etc., can solve problems such as side effects, achieve stable dose delivery rate, and avoid systemic side effects.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment A
[0094] The combination therapy of the present invention may be administered in the following clinical regimens.
[0095] Treatment options: Patients with chronic hepatitis C can receive 3 million IU of Intron A (interferon alfa-2b) parenterally once a week in combination with ribavirin at an oral dose of 350 mg / day. Synthetic polymers to form extended release dosage forms. Any study has two phases, the first phase lasts at least 28 weeks and compares the therapeutic effects of a liver-selective formulation of ribavirin with a conventional formulation given as a systemic formulation. The second phase of the study may be conducted in one or several subgroups of patients, with treatment lasting 68 weeks or longer, to ensure continuation of the treatment effect.
[0096] It is expected that use of lower doses of ribavirin (less than 400 mg / day or less than 6 mg / kg / day) combined with concentrations of ribavirin in the liver and portal circulation will substantially reduce side eff...
Embodiment B
[0098] Combination treatments of the present invention may be administered in the following clinical regimens.
[0099] Treatment options: Patients with chronic hepatitis C can receive 3 million IU of Intron A (interferon alpha-2b) parenterally once a week in combination with ribavirin at an oral dose of 600 mg / day. Synthetic polymers to form extended release dosage forms. Any study has two phases, the first phase lasts at least 28 weeks and compares the therapeutic effects of a liver-selective formulation of ribavirin with a conventional formulation given as a systemic formulation. Phase 2 studies in a subgroup or subgroups of patients, with treatment durations of 48 weeks or longer, are needed to ensure persistence of treatment effect.
[0100] It is expected that ribavirin administered in sustained release dosage form at higher doses will produce a more complete or rapid therapeutic response with fewer side effects than conventional or systemic doses.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com